House Democrats have launched aninvestigation intoKodak and the government office that issued it a $765 million loan to shift to drug production.- Rep.
Maxine Waters , the chair of the House Financial Services Committee, was among the Democratic leaders who sent a letter on Wednesday asking the US International Development Finance Corporation for all communications concerning the Kodak loan. - Democratic leaders also sent a letter to Kodak CEO Jim Continenza on Tuesday, The Wall Street Journal reported.
- On Tuesday, the Securities and Exchange Commission launched its own investigation into the Kodak announcement, following prompting by Sen. Elizabeth Warren.
- Watch Kodak trade live on Markets Insider.
- Read more on Business Insider.
A group of House Democrats has launched an investigation into Eastman Kodak's $765 million loan from a government agency.
In a letter released Wednesday, Democratic leaders including Rep. Maxine Waters, the House Financial Services Committee chair, asked the US International Development Finance Corporation, the agency responsible for the loan through the Defense Production Act, for all communications about the loan.
The group also questioned why the government office would support Kodak, "an organization that was on the brink of failure in 2012 and was unsuccessful in its previous foray into pharmaceutical manufacturing, in its efforts to develop the capacity to produce up to 25 percent of domestic pharmaceutical components."
On July 28, the
Shares of the company skyrocketed as much as 2,190% in two days. An uptick of more than 20% a day before the loan was announced drew scrutiny because of stock options granted to CEO Jim Continenza and other executives.
On Tuesday, the Securities and Exchange Commission launched its own investigation into irregular stock movements around the announcement of the loan.
The SEC investigation was urged by Sen. Elizabeth Warren, who wrote in a letter on Monday that "this is just the latest example of unusual trading activity involving a major Trump administration decision."
In a letter to Continenza on Tuesday, the group of Democratic leaders addressed concerns about the company's lack of pharmaceutical experience and the stock options granted to executives before the loan was announced, The Wall Street Journal reported on Wednesday.